Corexa Pharmacy Tops $1M Monthly Revenue, Up 66% Since July
MEDS has more than doubled off its 52-week low of $0.823 on light trading volume (0.1× avg).
Summary
Corexa Pharmacy, a division of DataMeds AI's wholly owned subsidiary, recorded preliminary unaudited revenue of more than $1 million for September 2026, a jump of over 66% from July. The growth is attributed to the rebranding completed early in Q3, the launch of Tollo Health's dietary supplements and medical foods, and an expanding retail customer base. This follows the recent Helomics acquisition and the rollout of the Health Lives Here mobile app, which positions Corexa as a fulfillment option for telehealth prescriptions. The company is also upgrading its physical location to serve as a flagship model for its network of over 6,500 independent pharmacies. While the revenue figure is modest relative to the company's overall losses and going-concern status, the rapid sequential growth in a key operating segment is a tangible positive signal for the turnaround narrative.
At the time of this announcement, MEDS was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.82 to $73.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.